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Introduction: Recent evidence demonstrates that women with myotonic dystrophy type
1 are at increased risk of reproductive organ tumors. However, studies of reproductive
cancer risk factors in those patients are lacking.
Methods: Using questionnaires, we collected and analyzed personal history information
related to cancer risk factors from women enrolled in a UK and US registry for myotonic
dystrophy (dystrophia myotonica; DM) patients.
Results: The survey was completed by 242 DM type 1 (DM1) and 44 DM type 2 (DM2)
women enrolled in the UK Registry (N = 124) and the US National Registry (N = 162).
The mean age at DM1 diagnosis was 33.8 years (standard deviation, SD = 13.2) and
for DM2 was 49.2 (SD = 13.0). Mean age at survey was 48.7 (SD = 12.8) and 59.1
years (SD = 12.8) for DM1 and DM2, respectively. There were no statistically significant
differences between DM1 and DM2 regarding menstrual history or fertility-related factors.
Yet, women with DM2 were more likely to have used menopausal hormone therapy
(HT) than women with DM1 (52.3 vs. 22.1%, p < 0.0001), and more women with
DM2 had a hysterectomy (53.5 vs. 29.5%, p < 0.01). These differences were not
statistically significant after age adjustment (OR = 2.00, p = 0.08, and OR = 1.40, p
= 0.38, respectively). The frequency of self-reported reproductive organ tumors was not
significantly different comparing DM1 to DM2 (p = 0.28). However, the data suggested
that women with DM2 appear to have a lower risk of malignant tumors compared to
those with DM1 (OR = 0.72, p = 0.69).
Discussion: Our study is the first to characterize a wide range of reproductive risk
factors in women with DM. We observed no significant differences between DM1
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and DM2 in the factors that were evaluated, which suggests that the known excesses
of ovarian and endometrial cancer previously reported in women with DM1 cannot be
attributed to greater prevalence of standard cancer-related reproductive risk factors.
Larger studies evaluating the possible link between reproductive cancer risk factors and
risk of tumors in women with DM are needed.
Keywords: myotonic dystrophy, Steinert’s disease, female reproductive factors, benign tumor, cancer,
endometrial cancer, ovarian cancer
INTRODUCTION
The myotonic dystrophies (dystrophia myotonica; DM), are
two inherited, multisystem, autosomal dominant disorders
that primarily affect skeletal muscle (1). Myotonic dystrophy
type 1 (DM1, “Steinert’s disease”) is caused by an unstable
trinucleotide (CTG) repeat expansion in the 3′-UTR of
the dystrophia myotonica-protein kinase (DMPK) gene
(2–4). Myotonic dystrophy type 2 (DM2) is caused by an
unstable tetranucleotide (CCTG) repeat expansion in the
CCHC-type zinc finger nucleic acid binding protein (CNBP)
gene (5, 6). Clinical phenotypes of DM1 and DM2 share
many features, including progressive muscle weakness,
myotonia, and other organ abnormalities, such as, cardiac
conduction defects, gastrointestinal alterations, endocrine
disturbances (especially insulin resistance), and characteristic
cataracts (7–9).
Recent evidence has shown that DM1 patients have an
increased risk of both benign and malignant tumors (10–13),
including those of the female reproductive organs. A large
population-based study used data from the Swedish and Danish
population-based patient registries to show that women with
DM have ∼5- and 8-fold higher risk of ovarian and endometrial
cancer than the general population, respectively (13). Studies
of the Basque DM1 cohort (14) and from France and the UK
(15, 16) observed similar findings. Cross-sectional studies from
Italy and the UK reveal that uterine fibroids are the most
commonly reported benign tumor in women with DM1 or
DM2 (17, 18).
A better understanding of the medical and family history
in DM1 and DM2 patients, combined with current standard
clinical assessment of female reproductive factors, may shed light
on potential risk factors for these cancers and in turn lead to
strategies for prevention and early detection. However, studies
with information related to female reproductive cancer risk
factors in DM are lacking. In this study, we report a wide range
of reproductive factors in women with DM1 or DM2, focusing
on risk of cancers of the female reproductive system, using data
collected from patients enrolled in DM registries from the US
and UK.
Abbreviations: CNBP, CCHC-type zinc finger nucleic acid binding protein; CTG,
Trinucleotide; CCTG, Tetranucleotide; CI, Confidence interval; DM, Myotonic
dystrophy; DM1, Myotonic dystrophy type 1; DM2, Myotonic dystrophy type 2;
DMPK, dystrophia myotonica-protein kinase; FSHD, US National Registry of DM
and Facioscapulohumeral Muscular Dystrophy; HT, Hormone therapy; OR, Odds
ratio; SD, Standard deviation; UF, Uterine fibroid.
MATERIALS AND METHODS
Study Population and Data Collection
This study included 286 women, genetically and/or clinically
confirmed as having DM and self-enrolled in the UK DM
Registry (19) (https://www.dm-registry.org/uk/; N = 124:
DM1 = 120, DM2 = 4) or the US National Registry
of DM and Facioscapulohumeral Muscular Dystrophy (20)
(US DM registry; https://www.urmc.rochester.edu/neurology/
national-registry.aspx; N = 162: DM1 = 122, DM2 = 40),
who responded to the reproductive history questionnaire. DM
diagnosis was confirmed by the patient-designated healthcare
professional in the UK and medical record review in the US
(19, 20).
Details describing the methodology of data collection and
information obtained have been published previously (18,
21, 22). Briefly, a self-administered questionnaire was sent
to DM patients enrolled in the US (via mail) or UK
(primarily via email, followed by mail for non-responders)
DM registries. The questionnaire requested information on
personal history of benign and malignant tumors, familial
history of cancer, and known cancer risk factors, including
reproductive history. Baseline demographic and DM clinical
factor data were obtained from relevant registry databases.
Research activities of the US DM registry were approved
by the University of Rochester’s Institutional Review Board,
and those of the UK DM Registry were approved by the
UK Research Ethics Service. This report is part of our
comprehensive effort aimed at more detailed characterization
of the recently-recognized cancer susceptibility in DM patients
(18, 21–23).
Collection of Female Reproductive Cancer
Risk Factor Information
The questionnaire collected the following information: age at
menarche, birth control pill use and duration, consultation for
infertility, pregnancy history (number of pregnancies and live-
born children), time of last regular menstrual period, menopausal
hormone therapy (HT) use and duration, and history of
hysterectomy. Information on history of gynecologic tumors
was determined from the patient’s response to the following
questions: “Have you ever been diagnosed with any benign (non-
cancerous) tumor?” and “Have you ever been diagnosed with
any type of cancer (a malignant growth or invasive tumor)?” If
patients responded “yes,” they were asked to specify the tumor
type/site and date- or age-at-diagnosis.
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Statistical Analysis
We used chi-square or Fisher’s exact test to compare the
frequency of categorical variables between DM1 and DM2
patients, and t-test for continuous variables. To minimize
the possible impact of confounding by age, we used logistic
regression models to adjust all comparisons for age at survey.
All analyses were conducted using SPSS Version 25.0 (IBM
Corp. Armonk, NY) with statistical significance defined as
two-sided p< 0.05.
RESULTS
Characteristics of Female DM Patients
Participating in the Study
DM patients enrolled from the US DM registry were older at
survey and at DM diagnosis (Table 1). In both countries, DM2
patients were older than DM1 patients (mean age at survey =
59.8 vs. 51.2, p = 0.0001 in the US; 52.2 vs. 46.2, p = 0.37 in the
UK). As expected, DM2 patients were diagnosed at an older age
(mean age at diagnosis = 49.7 vs. 33.7 in the US; 42.3 vs. 33.8 in
the UK), and were older at first DM2 symptom than those with
DM1 (mean age at first DM symptom= 35.9 vs. 26.8 years in the
US; 41.0 vs. 27.8 years in the UK).
Comparison of Female Reproductive
Factors Between DM1 and DM2 Patients
Table 2 summarizes female reproductive factors in patients with
DM1 and DM2. The median age at menarche was 13 years for
both DM1 and DM2 patients (DM1 range = 9–23, DM2 range
= 9–16). DM1 and DM2 patients reported similar use of oral
contraceptives, a higher frequency of self-reported menopausal
HT use in patients with DM2 was noted (52.3 vs. 22.1%, in DM2
and DM1, respectively, p < 0.0001). Hysterectomy was reported
by 33.3% of the patients (n = 89 among 267 responders); 56 of
TABLE 1 | Characteristics of female DM patients in the US and UK registries.
US (n = 162) UK (n = 124)
Patient characteristics n Mean (SD) n Mean (SD) P-valuea
Age, years
At survey 162 53.3 (12.6) 124 46.4 (13.2) <0.0001
At DM diagnosis 161 37.6 (15.0) 120 34.0 (12.9) 0.04
At first DM symptom 156 29.0 (15.0) 112 28.0 (13.7) 0.60
n % n %
DM subtype <0.0001
DM1 122 75.3 120 96.8
DM2 40 24.7 4 3.2
Race 0.20b
White 154 95.1 121 98.4
Other 8 4.9 2 1.6
DM, myotonic dystrophy; SD, standard deviation.
at-test for continuous variables and chi-square test for categorical variables unless
otherwise specified.
bFisher’s exact test.
whom also had oophorectomy. Approximately half of those with
hysterectomy (48.3%, N = 43) reported a history of gynecologic
tumor (DM1 patients = 32, 74.4%, DM2 patients = 11, 25.6%).
Surgical menopause (hysterectomy and/or oophorectomy) was
the most common reason for cessation of menses (≥6 months)
in both DM1 and DM2.
Gynecological tumors were reported by more than one-
fourth of the patients. DM1 patients reported 64 benign (in
54 patients), and 10 malignant gynecological tumors (in 10
patients). DM2 patients reported 19 benign (in 15 patients) and 2
malignant gynecological tumors (in 2 patients). Overall, uterine
fibroids were the most frequent benign tumor (N = 46 patients,
prevalence= 16.7%), followed by ovarian cysts (N = 33 patients,
prevalence = 12.0%). For malignant tumor, 6 women (2.2%)
reported ovarian cancer, 4 reported endometrial or uterine cancer
(1.4%), and 2 reported cervical cancer (0.7%). Among the 12
women with a gynecologic cancer, 5 reported that they also had a
benign gynecological tumor.
In age-adjusted analyses, no statistically significant differences
between DM1 and DM2were noted in any of the factors analyzed
(Table 3). However, the data suggested that DM2 patients may
be more likely to have undergone hysterectomy (OR = 1.40,
p = 0.38) or receive menopausal HT (OR = 2.00, p = 0.08),
and less likely to have infertility-related consultations (OR =
0.74, p = 0.49), or malignant tumors of the reproductive organs
(OR= 0.72, p= 0.69).
DISCUSSION
In this cross-sectional study of 286 womenwith DM1 or DM2, we
explored differences in reproductive cancer risk factors by DM
subtype. Age-adjusted analyses showed no statistically significant
differences; however, the data suggested that DM2 patients may
be more likely to have undergone hysterectomy and to have used
menopausal HT.
In this study, we observed similar ages at menarche for women
with DM1 or DM2 (median = 13 years). This was similar to
age at menarche reported in the US general population based on
data from 2,510 children and adolescents of non-Hispanic whites,
blacks, and Mexican Americans in the third National Health and
Nutrition Examination Survey (median = 12.4 years) (24). For
age at menopause, we did not directly collect this information.
However, most patients (DM1 = 91.3%, DM2 = 100%) who
reported natural menopause were >50 years old at survey. The
median age of natural menopause in the US is 52.6 years (25). On
the other hand, 81 patients reported surgical menopause, 21 of
which (26%) occurred at or before age 50. One-third of the DM
patients in the current study reported a history of hysterectomy.
The US prevalence for women 15–44 years of age is 4.0% (26, 27).
In the UK, the estimated prevalence of hysterectomy for all ages
is approximately 9%, with a peak increase at age 55 and older
that reaches 20% (28). Similar to previous studies in DM (17,
18), uterine fibroids were common, affecting 16.7% of the DM
patients, followed by ovarian cysts, affecting 12%. The prevalence
of uterine fibroids noted in this study is higher than that reported
in the general population from the US (6.9%) and UK (4.5%)
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TABLE 2 | Selected female reproductive cancer risk factors among women with DM by disease subtype.
DM1 (n = 242) DM2 (n = 44)
Female reproductive factors N responded Mean (SD) or N (%) N responded Mean (SD) or N (%) P-valuea
Birth control pill use 167 36 0.60b
Ever 145 (86.8%) 30 (83.3%)
Never 22 (13.2%) 6 (16.7%)
Years on birth control pill 116 8.98 (7.9) 29 7.79 (7.6) 0.47
Fertility-related consultation 152 35 0.36
Ever 56 (36.8%) 10 (28.6%)
Never 96 (63.2%) 25 (71.4%)
Pregnancy 225 42 0.34
Ever 149 (66.2%) 31 (73.8%)
Never 76 (33.8%) 11 (26.2%)
Number of live births; mean (SD) 126 1.95 (0.9) 29 2.31 (1.2) 0.15c
1 44 (34.9%) 8 (27.6%) 0.44c
2–3 70 (55.6%) 16 (55.2%)
≥4 12 (9.5%) 5 (17.2%)
Reason no menstrual period ≥6 months 141 37 0.05
Natural menopause as the reason 46 (32.6%) 16 (43.2%)
Surgery to remove uterus or ovaries 62 (44.0%) 19 (51.4%)
Other reasons 33 (23.4%) 2 (5.4%)
Menopausal HT use 213 44 <0.0001
Ever 47 (22.1%) 23 (52.3%)
Never 166 (77.9%) 21 (47.7%)
Years on menopausal HT 42 8.19 (9.1) 22 7.43 (8.4) 0.75
Hysterectomyd 224 43 <0.01
Ever 66 (29.5%) 23 (53.5%)
Never 158 (70.5%) 20 (46.5%)
Gynecologic tumor history 232 43 0.28
Benign onlye 50 (21.6%) 14 (32.6%)
Malignant ± benigne 10 (4.3%) 2 (4.6%)
No gynecologic tumor history 172 (74.1%) 27 (62.8%)
DM, myotonic dystrophy; SD, standard deviation.
at-test for continuous variables and chi-square test for categorical variables unless otherwise specified.
bFisher’s exact test.
cp-value comparing number of live births = 0.15; p-value comparing frequencies of 1, 2–3, ≥4 live births between DM1 and DM2 = 0.44.
dAmong N = 89 women who were hysterectomized, N = 56 women also reported a history of oophorectomy.
eBenign only (n = 69 patients): uterine fibroid (n = 46), ovarian cysts (n = 33), uterine fibroid + ovarian cysts (n = 12), other gynecologic benign tumor (n = 4); malignant only (n = 7
patients): endometrial or uterine cancer (n = 3), ovarian cancer (n = 3), cervical cancer (n = 1); benign + malignant (n = 5 patients): ovarian cysts + cervical cancer (n = 1), ovarian
cysts + endometrial or uterine cancer (n = 1), ovarian cysts + ovarian cancer (n = 1), uterine fibroids + ovarian cancer (n = 1), uterine fibroids, ovarian cysts + ovarian cancer (n = 1).
in a large study of 21,746 women aged 15–49 years from eight
countries (29).
The molecular basis underlying tumor development in the
female reproductive systems among DM patients has yet to
be identified. Ongoing studies seek a better understanding of
whether DM disease severity correlates with tumor development.
Alsaggaf et al. have provided the first data suggesting that DM1-
related cancer susceptibility may be positively correlated with
disease severity in adult onset DM1 (16). Upregulation of Wnt-
β-catenin signaling (30) and loss of DMPK heterozygosity have
been hypothesized as etiologically important (31). Interestingly,
a recent gene expression analysis showed microRNA-200c
and microRNA-141 tumor suppressor gene expression is sex-
dependent in DM1, in which significant downregulation was
observed among female DM1 patients (14). Downregulation
of miRNA-200c and miRNA141 were implicated in uterine
fibroid (32) and endometriosis (33) pathogenesis, respectively.
Additionally, dysregulation of miR-200 family has been
associated with ovarian cancer (34) and endometrial cancer
development (35).
Our current investigation is the first study to characterize a
wide range of reproductive risk factors in women with DM. The
strengths of our current study include its relatively large sample
size, representation of DM patients from two countries, and
DM diagnosis having been validated by medical professionals.
Our investigation is limited by the self-reported nature of the
collected information. Since the study analyzed data from DM
patients who were self-enrolled in the DM registries, the results
may not be generalizable to the entire DM population. However,
our study population did have similar distribution of age-at-
diagnosis to the DM general population. Our study focused
on DM patients and lacked matched control comparisons, so
we used published general population estimates which may not
be age comparable to our study population. Our questionnaire
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TABLE 3 | Age-adjusted comparison of key female reproductive cancer risk
factors between patients with DM2 vs. DM1.
Female reproductive factors Adjusted OR 95% CI P-value
Ever use of birth control pill 1.20 (0.42–3.43) 0.73
Infertility-related consultation 0.74 (0.32–1.72) 0.49
Ever been pregnant 0.78 (0.34–1.77) 0.55
Ever used menopausal HT 2.00 (0.93–4.31) 0.08
Hysterectomya 1.40 (0.66–2.98) 0.38
Gynecologic tumor historyb
Benign tumor only 1.15 (0.53–2.49) 0.72
Malignant cancer 0.72 (0.14–3.72) 0.69
DM1, myotonic dystrophy type1; DM2, myotonic dystrophy type2; OR, odds ratio; CI,
confidence interval.
aAmong N = 267 who responded to “hysterectomy ever”. Reference: women who never
had hysterectomy.
bAmong N = 275 who responded to the cancer and tumor history questionnaires.
Reference: women with no gynecologic tumor history.
lacked information on birth control methods other than pills
such as injections. Due to the small number of reported cancers in
study participants, we were not able to formally test associations
between reproductive factors and risk of specific neoplasms. Also,
our reported frequencies may be overestimated in situations
of missing information due to patient non-response since
denominators were only based on the number of responders.
In conclusion, our study found no significant reproductive
cancer factor differences between female DM1 and DM2 subjects,
except for a possibility of a higher frequency of hysterectomy
and HT use in DM2 patients. The older age of the DM2 patient
cohort may have contributed to these observed differences.
The observed similarities between DM1 and DM2 cohorts
regarding menstrual history or fertility-related factors suggest
that the known excesses of ovarian and endometrial cancer
seen in DM1 subjects cannot be attributed to greater prevalence
of standard gynecologic cancer risk factors. In the future,
larger studies evaluating the possible link between reproductive
cancer risk factors and risk of tumors in women with DM
are needed.
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